Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Fresno. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Fresno at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause t
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this glioblastoma clinical trial in Fresno, CA
If you're searching for glioblastoma treatment options in Fresno, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Fresno research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.